SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript [Seeking Alpha]
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million [Yahoo! Finance]
SCYNEXIS announces $40M private placement [Seeking Alpha]
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Yahoo! Finance]
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million